Figures on vaccination
- 51.5 million doses delivered in the EU
- 29.2 million doses administered in the EU
Latest update: 26 February 2021. Source: Vaccine producers and the ECDC data
Preparing for COVID-19 variants and securing additional vaccines
On 17 February, the Commission presented the “HERA Incubator”, new European bio-defence preparedness plan against COVID-19 variants. The Incubator will bring together science, industry and public authorities and pull all available resources to prepare Europe for this challenge.
On the same day, the Commission also secured 300 million more doses of the proven safe and effective vaccine from Moderna, enlarging the EU’s vaccine portfolio to 2.6 billion of doses.
Information about vaccination in the EU
Securing doses of future vaccines
The European Commission has been negotiating intensely to build a diversified portfolio of vaccines for EU citizens at fair prices. Contracts have been concluded with 6 promising vaccine developers, securing a portfolio of more than 2.6 billion doses.
Deliveries of vaccine doses to European Union countries have increased steadily since December. Vaccination gathers pace across the European Union.
The Commission has so far given 3 conditional marketing authorisations for the vaccines developed by BioNTech and Pfizer, Moderna and AstraZeneca following EMA positive assessment of their safety and efficacy. Several other vaccines are at different stages of assessment by the European Medicines Agency (EMA).
The Commission is working closely with the industry to step up vaccine manufacturing capacity in the EU.
At the same time, the Commission has started work to anticipate and tackle new variants of the virus and to rapidly develop and produce on a large-scale vaccines effective against those variants.
This is why the European Commission has launched the HERA Incubator. It will bring together science, industry and public authorities, to speed up work and leverage all available resources to enable Europe to respond to this threat.
- 2.6 billion doses
Type of vaccine
Number of doses
(needed per person)
Number of doses
|BioNTech and Pfizer||mRNA||2 doses||600 million||Approved|
|Moderna||mRNA||2 doses||460 million||Approved|
|CureVac||mRNA||2 doses||405 million||Development ongoing|
|AstraZeneca||adenovirus||2 doses||400 million||Approved|
|Johnson & Johnson/Janssen Pharmaceuticals||adenovirus||1 dose||400 million||Under evaluation by EMA|
|Sanofi-GSK||protein||2 doses||300 million||Development ongoing|
The Commission has also concluded exploratory talks with
- Novavax with a view to purchasing up to 200 million doses, and
- Valneva with a view to purchase up to 60 million doses.
The European Medicines Agency (EMA) released on 29 January its first safety update on a COVID-19 vaccine — Comirnaty, a vaccine produced by BioNTech and Pfizer. It concluded that safety data collected on Comirnaty use in vaccination campaigns was consistent with the known safety profile of the vaccine, and no new side effects were identified.
- Reports of suspected severe allergic reaction have not identified new aspects regarding the nature of this known side effect.
- No specific safety concern has been identified for vaccine use in frail elderly individuals.
- Its benefits in preventing COVID-19 continue to outweigh any risks, and there are no recommended changes regarding the use of the vaccine.
Check the facts
Disinformation on the coronavirus is thriving. It is important that you get updated information from authoritative sources only. We suggest that you follow the advice of your public health authorities, and the websites of relevant EU and international organisations: the European Centre for Disease Control (ECDC ) and the World Health Organisation (WHO).
You can also help by not sharing unverified information that comes from dubious sources.
The EU vaccine strategy
With the EU Vaccine Strategy, the EU is supporting efforts to accelerate the development and availability of safe and effective vaccines in a timeframe between 12 and 18 months, if not earlier. Delivering on this complex task requires running clinical trials in parallel with investing in production capacity to be able to produce millions, or even billions, of doses of a successful vaccine.
Hear from the experts
Peter Piot, virologist
Dr Frank Ulrich Montgomery,
Hear from the people
Borislava Ananieva, transplant patient